# Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

> **NCT00066352** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto**

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00066352
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2003-09
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066352, "Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00066352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*